Clinical trial
Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
To determine the maximum tolerated dose (MTD) of Dasatinib in relapsed or refractory non-hodgkin's lymphoma (NHL) patients and to determine the safety of Dasatinib in NHL.
| Category | Value |
|---|---|
| Study start date | 2007-10-26 |